Detalles de la búsqueda
1.
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
Clin Transl Oncol
; 25(12): 3556-3564, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37217634
2.
Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients.
Cancers (Basel)
; 13(13)2021 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34209601
3.
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
Clin. transl. oncol. (Print)
; 25(12): 3556-3564, dec. 2023.
Artículo
en Inglés
| IBECS (España) | ID: ibc-227299
Resultados
1 -
3
de 3
1
Próxima >
>>